APA (7th ed.) Citation

TS, M., Y, C., X, Z., KH, L., K, N., S, N., . . . YL, W. (2018). Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 36(22), 2244. https://doi.org/10.1200/JCO.2018.78.7994

Chicago Style (17th ed.) Citation

TS, Mok, et al. "Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 36, no. 22 (2018): 2244. https://doi.org/10.1200/JCO.2018.78.7994.

MLA (9th ed.) Citation

TS, Mok, et al. "Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 36, no. 22, 2018, p. 2244, https://doi.org/10.1200/JCO.2018.78.7994.